HITIQ’s $250K Placement at 22% Premium Plus $1.4M RDTI Loan Secured

Strategic Capital Raise

HITIQ Ltd (ASX, HIQ), a medical technology company specialising in concussion management, has successfully completed a $250,000 placement of shares to a sophisticated investor. The shares were issued at 2.2 cents each, representing a notable 22.2% premium to the closing price on 26 September 2025. Alongside the shares, investors received attaching options exercisable at the same price, expiring in December 2028, consistent with terms from a recent rights issue.

This placement, executed without a lead manager, reflects HITIQ’s ongoing efforts to strengthen its capital base while maintaining shareholder value. The premium pricing signals investor confidence in the company’s strategic direction and technology potential.

New RDTI Loan Facility

Complementing the placement, HITIQ has entered into a $1.4 million Research and Development Tax Incentive (RDTI) loan facility with No Bull Health Pty Ltd, a related party linked to the company’s largest shareholder, Harmil Angel Investments. An initial drawdown of $480,000 has already been made, with the remainder available over the next year.

The loan carries a 12% annual interest rate and a 365-day maturity, with an application fee of $5,500. While initially unsecured, HITIQ plans to seek shareholder approval at its upcoming AGM to secure the loan against eligible R&D expenditure, a move that would align with standard practices for such facilities.

Backing the Consumer Market Pivot

The capital raised through both the placement and the RDTI loan is earmarked to support HITIQ’s strategic pivot towards commercialising its concussion management technology for the consumer market. Executive Chairman Earl Eddings highlighted the value of the company’s relationship with Harmil Angel Investments, noting their strategic insights into consumer product businesses as a key asset during this transition.

This funding round underscores HITIQ’s commitment to scaling its impact IQ technology beyond clinical settings, aiming to capture growing demand for accessible concussion management solutions among consumers.

Looking Ahead

As HITIQ prepares for its AGM and further capital deployment, investors will be watching closely for the approval of loan security arrangements and the company’s progress in penetrating consumer markets. The attaching options issued with the placement shares also introduce a potential dilution factor that market participants will need to monitor.